Jazz Pharmaceuticals
JAZZ
499 hedge funds and large institutions have $7.12B invested in Jazz Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 165 increasing their positions, 179 reducing their positions, and 58 closing their positions.
36% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 58
22% more call options, than puts
Call options by funds: $41M | Put options by funds: $33.5M
3% more funds holding
Funds holding: 484 → 499 (+15)
2.49% more ownership
Funds ownership: 89.51% → 92% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $7.33B → $7.12B (-$203M)
8% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 179
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$92.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$84.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$80.6M |
| 4 |
AC
Armistice Capital
New York
|
+$42.3M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$28.1M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$136M |
| 2 |
SC
Samlyn Capital
New York
|
-$91.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$48.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$38.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$38.5M |
JAZZ Hedge Fund Activity: Q4 2023 in Review
499 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2023, worth a combined $7.12B — down 2.8% from $7.33B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new JAZZ positions and 58 closed out — a net gain of 21 holders — while 165 added to existing stakes and 179 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $92.6M. The largest seller was Deep Track Capital, cutting an estimated $136M.
- 499 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2023, up from 484 in Q3 2023.
- Funds reported $7.12B of Jazz Pharmaceuticals stock for Q4 2023, down 2.8% quarter-over-quarter.
- 79 funds opened new Jazz Pharmaceuticals positions in Q4 2023 and 58 closed out, a net change of +21 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $92.6M added.
- The largest Jazz Pharmaceuticals seller in Q4 2023 was Deep Track Capital, an estimated $136M sold.
Based on aggregated 13F filings for Q4 2023.